Compare Stocks → Top Project Outperforms BTC in 2023… (From Crypto 101 Media) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:CLRBNASDAQ:EYEGNASDAQ:INNTOTCMKTS:MCUJF Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCLRBCellectar Biosciences$3.98+9.6%$3.68$1.30▼$4.45$48.91M0.931.88 million shs1.77 million shsEYEGAB Corporate Bond ETF$35.75+0.1%$1.90$1.44▼$8.18$451.12M0.81935,975 shsN/AINNTInnovate Biopharmaceuticals$0.97$0.37▼$1.67$8K-0.39525,982 shs253 shsMCUJFMedicure$0.85$0.90$0.69▼$1.26$8.87M0.92703 shsN/A10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCLRBCellectar Biosciences-5.58%-2.55%+4.15%+45.98%+155.99%EYEGAB Corporate Bond ETF+0.43%+0.71%+1.31%-0.98%+1,732.20%INNTInnovate Biopharmaceuticals0.00%0.00%0.00%0.00%-99.92%MCUJFMedicure0.00%+11.27%-10.34%+9.62%+14.59%Top Project Outperforms BTC in 2023… (Ad)According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.Just click here for instant access to the #1 Coin for 2024.MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCLRBCellectar Biosciences2.5837 of 5 stars3.54.00.00.03.70.00.6EYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCLRBCellectar Biosciences3.00Buy$20.00402.51% UpsideEYEGAB Corporate Bond ETFN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/ACurrent Analyst RatingsLatest CLRB, MCUJF, INNT, and EYEG Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/28/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$20.00 ➝ $28.003/28/2024CLRBCellectar BiosciencesOppenheimerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.003/4/2024CLRBCellectar BiosciencesRoth MkmSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00(Data available from 3/28/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCLRBCellectar BiosciencesN/AN/AN/AN/A$1.51 per shareN/AEYEGAB Corporate Bond ETF$10K45,112.29N/AN/A$1.26 per share28.37INNTInnovate BiopharmaceuticalsN/AN/AN/AN/A($0.27) per shareN/AMCUJFMedicure$17.74M0.50$0.26 per share3.31$1.58 per share0.54Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCLRBCellectar Biosciences-$28.60M-$3.25N/AN/AN/AN/A-3,821.29%-207.04%5/2/2024 (Estimated)EYEGAB Corporate Bond ETF-$8.09M-$1.68N/AN/AN/AN/A-104.96%-60.03%N/AINNTInnovate Biopharmaceuticals-$27.05MN/AN/AN/AN/AN/AN/A-234.42%N/AMCUJFMedicure$1.05M$0.0712.14∞N/A4.70%4.99%3.63%4/4/2024 (Estimated)DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCLRBCellectar BiosciencesN/AN/AN/AN/AN/AEYEGAB Corporate Bond ETFN/AN/AN/AN/AN/AINNTInnovate BiopharmaceuticalsN/AN/AN/AN/AN/AMCUJFMedicureN/AN/AN/AN/AN/ALatest CLRB, MCUJF, INNT, and EYEG DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date2/29/2024EYEGAB Corporate Bond ETFMonthly$0.14863/1/20243/4/20243/7/20241/31/2024EYEGAB Corporate Bond ETFMonthly$0.14762/1/20242/2/20242/7/2024(Data available from 1/1/2013 forward)DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCLRBCellectar BiosciencesN/A1.221.22EYEGAB Corporate Bond ETF0.013.073.07INNTInnovate BiopharmaceuticalsN/A0.350.35MCUJFMedicure0.012.281.78OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCLRBCellectar Biosciences16.41%EYEGAB Corporate Bond ETF64.16%INNTInnovate Biopharmaceuticals5.88%MCUJFMedicureN/AInsider OwnershipCompanyInsider OwnershipCLRBCellectar Biosciences4.60%EYEGAB Corporate Bond ETF58.20%INNTInnovate Biopharmaceuticals7.90%MCUJFMedicure12.90%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableCLRBCellectar Biosciences1512.29 million11.72 millionOptionableEYEGAB Corporate Bond ETF1412.62 million5.28 millionNot OptionableINNTInnovate Biopharmaceuticals841.33 millionN/ANot OptionableMCUJFMedicureN/A10.44 million9.09 millionNot OptionableCLRB, MCUJF, INNT, and EYEG HeadlinesSourceHeadlineMedicure (OTCMKTS:MCUJF) Stock Crosses Below Two Hundred Day Moving Average of $1.00americanbankingnews.com - March 21 at 4:22 AMANNOUNCEMENTS ON Poly Medicuremoneycontrol.com - March 9 at 11:01 PMMedicure Announces New Partnership Through Its Marley Drug Subsidiary to Provide Brenzavvy(R) as an Affordable Medication for Americans with Type 2 Diabetesfinance.yahoo.com - December 5 at 5:41 PMMedicure approved to enrol patients in paediatric disease trialmsn.com - November 24 at 6:24 PMMedicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Diseasebenzinga.com - November 23 at 7:03 PMPoly Medicure Ltd (POLYMED) Share Pricebusinesstoday.in - November 21 at 7:15 PMMedicure GAAP EPS of C$0.01, revenue of C$5Mmsn.com - November 21 at 7:15 PMMedicure Reports Financial Results for Quarter Ended September 30, 2023finance.yahoo.com - November 21 at 7:15 PMMedicure Inc.'s (CVE:MPH) Stock Is Going Strong: Have Financials A Role To Play?finance.yahoo.com - October 24 at 7:52 AMMedicure: Top 10 Undervalued Drug Manufacturers Industry Stocks (MPH)theglobeandmail.com - October 2 at 8:16 AMClosing Bell: Medicure Inc flat on Thursday (MPH)theglobeandmail.com - August 25 at 3:26 PMClosing Bell: Medicure Inc flat on Monday (MPH)theglobeandmail.com - August 15 at 7:48 AMTrade Spotlight | Your trading strategy for Syngene International, Poly Medicure, Raymond todaymoneycontrol.com - August 1 at 7:10 AMClosing Bell: Medicure Inc flat on Friday (MPH)theglobeandmail.com - July 29 at 10:12 AMMedicure Reports Financial Results For Quarter Ended June 30, 2023finance.yahoo.com - July 29 at 12:11 AMMedicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023finance.yahoo.com - July 24 at 11:15 PMPoly Medicurelivemint.com - July 22 at 10:43 AMPoly Medicure Ltd.ndtv.com - May 31 at 1:13 PMMedicure Reports Financial Results for Quarter Ended March 31, 2023finance.yahoo.com - May 26 at 7:58 PMClosing Bell: Medicure Inc down on Tuesday (MPH)theglobeandmail.com - May 24 at 10:56 AMPoly Medicure Limited (POLYMED.NS)finance.yahoo.com - May 21 at 1:19 AMClosing Bell: Medicure Inc up on Friday (MPH)theglobeandmail.com - May 5 at 9:41 PMMedicure Reports Financial Results for Quarter and Year Ended December 31, 2022finance.yahoo.com - April 6 at 7:28 PMMedicure To Present Financial Results on April 10, 2023 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2022finance.yahoo.com - April 5 at 2:52 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsCellectar BiosciencesNASDAQ:CLRBCellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.AB Corporate Bond ETFNASDAQ:EYEGEyeGate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company, which engages in the development and commercialization of products for treating diseases and disorders of the eye. Its pipeline includes MoxiGel and Ocular Bandage Gel. The company was founded in 1998 and is headquartered in Waltham, MA.Innovate BiopharmaceuticalsNASDAQ:INNTInnovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase IIb clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase I clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease, as well as product for the treatment of alcoholic steatohepatitis (ASH). In addition, the company holds rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase III clinical trial. The company has a research collaboration with Massachusetts General Hospital for the treatment of ASH. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.MedicureOTCMKTS:MCUJFMedicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail and mail order pharmacies. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.